Merit Financial Group
ADMA icon

Merit Financial Group’s ADMA Biologics ADMA Stock Holding History

Merit Financial Group’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$868K Buy
86,509
+759
+0.9% +$7.02K ﹤0.01% 1239
2026
Q2 		$718K Buy
85,750
+11,306
+15% +$103K ﹤0.01% 1273
2026
Q1 		$671K Buy
74,444
+63,850
+603% +$1.01M 0.01% 1194
2025
Q4 		$193K Buy
+10,594
New +$179K ﹤0.01% 1831

Other funds holding ADMA

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Ranger Investment Management
Ranger Investment Management Dallas, Texas $1.07B AUM 31.98% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Marathon Capital Management
Marathon Capital Management Hunt Valley, Maryland $488M AUM 28.5% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Bridge City Capital
Bridge City Capital Lake Oswego, Oregon $480M AUM 47.16% 1-Year Est. Return

Merit Financial Group's ADMA Position: Q3 2026 in Review

Merit Financial Group increased its ADMA Biologics (ADMA) stake by 0.89% in Q3 2026, buying an estimated $7.02K and bringing the position to 86,509 shares worth $868K. The position accounts for ﹤0.01% of the portfolio, ranked #1239.

Merit Financial Group first reported a position in ADMA in Q4 2025 and has held it in 4 quarters since. 144 funds tracked by Wall St. Rank hold ADMA as of Q3 2026.

  • Merit Financial Group held 86,509 shares of ADMA Biologics worth $868K as of Q3 2026.
  • Merit Financial Group bought 759 ADMA Biologics shares in Q3 2026, an estimated $7.02K.
  • ADMA Biologics made up ﹤0.01% of Merit Financial Group's portfolio in Q3 2026, its #1239 holding.
  • Merit Financial Group first reported a position in ADMA Biologics in Q4 2025 and has held it in 4 quarters since.
  • 144 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2026.

Based on Merit Financial Group's 13F filing for Q3 2026, filed 6 Nov 2026.